Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Chief Legal Officer | February 02, 2026 | February 04, 2026 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Chief Legal Officer | June 15, 2023 | June 20, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bicara Therapeutics Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.76 · Expires 2036-02-02 | Direct | 90,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 90,000 · Balance 90,000 F1: The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.
Viridian Therapeutics, Inc.\DE
Report date June 15, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,971 |
Ending reported balance
After 2023-06-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-06-15 · Exercise / conversion · Acquired 2,269 · Balance 32,240 Row 2 · 2023-06-15 · Sale · Disposed 2,269 · Balance 29,971 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2023-06-16 · Exercise / conversion · Acquired 27 · Balance 29,998 Row 4 · 2023-06-16 · Sale · Disposed 27 · Balance 29,971 F2: This transaction was executed pursuant to the Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2031-01-18 | Direct | 37,481 |
Reported balance
After 2023-06-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-15 · Exercise / conversion · Disposed 2,269 · Balance 37,481 F3: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2031-01-18 | Direct | 37,453 |
Reported balance
After 2023-06-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-16 · Exercise / conversion · Disposed 28 · Balance 37,453 F3: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed pursuant to the Plan.
F3: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 4, 2026 21:34 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $16.76 | $0.00 |
DisclosureSEC source: 0001628280-26-005474 · wk-form4_1770240841.xml · derivative · entry 1 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:57 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,807 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001883986-25-000009 · wk-form4_1759352250.xml · derivative · entry 3 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,423 Underlying: Common Stock · 33,807 shares Expires 2034-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. F2 · derivative.exercise_date: 25% of the shares underlying this option vested on August 13, 2025, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:57 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 33,807 | $14.75 | $498,653.25 |
DisclosureSEC source: 0001883986-25-000009 · wk-form4_1759352250.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. Read SEC document |
| September 29, 2025 Filed Oct 1, 2025 20:57 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 33,807 | $9.24 | $312,495.00 |
DisclosureSEC source: 0001883986-25-000009 · wk-form4_1759352250.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:01 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,744 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001883986-25-000006 · wk-form4_1758142866.xml · derivative · entry 4 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,699 Underlying: Common Stock · 9,744 shares Expires 2033-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. F4 · derivative.exercise_date: 25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:01 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,085 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001883986-25-000006 · wk-form4_1758142866.xml · derivative · entry 3 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,769 Underlying: Common Stock · 6,085 shares Expires 2033-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:01 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 15,829 | $11.49 | $181,875.21 |
DisclosureSEC source: 0001883986-25-000006 · wk-form4_1758142866.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.34 to $11.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:01 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 15,829 | $5.45 | $86,268.05 |
DisclosureSEC source: 0001883986-25-000006 · wk-form4_1758142866.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 21:12 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,744 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0002023658-25-000085 · wk-form4_1750281133.xml · derivative · entry 4 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,443 Underlying: Common Stock · 9,744 shares Expires 2033-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. F4 · derivative.exercise_date: 25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 21:12 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,085 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0002023658-25-000085 · wk-form4_1750281133.xml · derivative · entry 3 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,854 Underlying: Common Stock · 6,085 shares Expires 2033-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 21:12 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 15,829 | $10.43 | $165,096.47 |
DisclosureSEC source: 0002023658-25-000085 · wk-form4_1750281133.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.03 to $10.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 21:12 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 15,829 | $5.45 | $86,268.05 |
DisclosureSEC source: 0002023658-25-000085 · wk-form4_1750281133.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:35 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,246 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0000950170-25-041546 · ownership.xml · derivative · entry 5 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,119 Underlying: Common Stock · 30,246 shares Expires 2033-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. F5 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:35 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 48,720 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0000950170-25-041546 · ownership.xml · derivative · entry 4 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,187 Underlying: Common Stock · 48,720 shares Expires 2033-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. F4 · derivative.exercise_date: 25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:35 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 30,620 | $13.24 | $405,512.91 |
DisclosureSEC source: 0000950170-25-041546 · ownership.xml · nonDerivative · entry 3 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.05 to $13.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:35 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 48,526 | $12.69 | $615,697.89 |
DisclosureSEC source: 0000950170-25-041546 · ownership.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,620 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.05 to $13.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:35 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 79,146 | $5.45 | $431,345.70 |
DisclosureSEC source: 0000950170-25-041546 · ownership.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2024. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:23 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-23-015998 · doc4.xml · derivative · entry 6 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,453 Underlying: Common Stock · 28 shares Expires 2031-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:23 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 27 | $28.35 | $765.45 |
DisclosureSEC source: 0000899243-23-015998 · doc4.xml · nonDerivative · entry 4 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,971 F2 · kind: This transaction was executed pursuant to the Plan. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:23 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 27 | $23.03 | $621.81 |
DisclosureSEC source: 0000899243-23-015998 · doc4.xml · nonDerivative · entry 3 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:23 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,269 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-23-015998 · doc4.xml · derivative · entry 5 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,481 Underlying: Common Stock · 2,269 shares Expires 2031-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:23 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 2,269 | $28.02 | $63,577.38 |
DisclosureSEC source: 0000899243-23-015998 · doc4.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,971 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:23 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 2,269 | $23.03 | $52,255.07 |
DisclosureSEC source: 0000899243-23-015998 · doc4.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2023 Filed Jun 6, 2023 23:41 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,126 | $0.00 Strike: $18.51 | $0.00 |
DisclosureSEC source: 0000899243-23-014615 · doc4.xml · derivative · entry 9 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,375 Underlying: Common Stock · 5,126 shares Expires 2032-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 06, 2023 Filed Jun 6, 2023 23:41 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 5,126 | $25.02 | $128,252.52 |
DisclosureSEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 6 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,971 F3 · kind: This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.00 to $25.155. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · price: This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.00 to $25.155. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 06, 2023 Filed Jun 6, 2023 23:41 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 5,126 | $18.51 | $94,882.26 |
DisclosureSEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 5 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2023 Filed Jun 6, 2023 23:41 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 499 | $0.00 Strike: $18.51 | $0.00 |
DisclosureSEC source: 0000899243-23-014615 · doc4.xml · derivative · entry 8 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,501 Underlying: Common Stock · 499 shares Expires 2032-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 05, 2023 Filed Jun 6, 2023 23:41 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 499 | $25.03 | $12,489.97 |
DisclosureSEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 4 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,971 F2 · kind: This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.02 to $25.035. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · price: This transaction was executed pursuant to the Plan in multiple trades at prices ranging from $25.02 to $25.035. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 05, 2023 Filed Jun 6, 2023 23:41 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 499 | $18.51 | $9,236.49 |
DisclosureSEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 3 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 23:41 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,875 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014615 · doc4.xml · derivative · entry 7 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,128 Underlying: Common Stock · 1,875 shares Expires 2031-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 23:41 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 1,875 | $24.21 | $45,393.75 |
DisclosureSEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,971 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $23.89 to $24.61. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $23.89 to $24.61. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 23:41 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 1,875 | $14.00 | $26,250.00 |
DisclosureSEC source: 0000899243-23-014615 · doc4.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:05 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 29,971 | $29.07 | $871,256.97 |
DisclosureSEC source: 0000899243-23-007996 · doc4.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.23 to $29.81. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.23 to $29.81. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 21:47 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 108,000 | $0.00 Strike: $34.20 | $0.00 |
DisclosureSEC source: 0000899243-23-004588 · doc4.xml · derivative · entry 1 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,000 Underlying: Common Stock · 108,000 shares Expires 2033-02-08 F1 · derivative.exercise_date: The option vests in equal monthly installments through February 8, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 23:04 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,872 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002674 · doc4.xml · derivative · entry 5 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,003 Underlying: Common Stock · 1,872 shares Expires 2031-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 23:04 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,971 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-23-002674 · doc4.xml · derivative · entry 4 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,750 Underlying: Common Stock · 4,971 shares Expires 2031-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 23:04 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 6,843 | $35.66 | $244,021.38 |
DisclosureSEC source: 0000899243-23-002674 · doc4.xml · nonDerivative · entry 3 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 23:04 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 1,872 | $14.00 | $26,208.00 |
DisclosureSEC source: 0000899243-23-002674 · doc4.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 23:04 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 4,971 | $23.03 | $114,482.13 |
DisclosureSEC source: 0000899243-23-002674 · doc4.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:42 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,326 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-22-039217 · doc4.xml · derivative · entry 6 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,721 Underlying: Common Stock · 16,326 shares Expires 2031-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:42 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 16,326 | $29.19 | $476,555.94 |
DisclosureSEC source: 0000899243-22-039217 · doc4.xml · nonDerivative · entry 4 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.01 to $29.5665. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.01 to $29.5665. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:42 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 16,326 | $23.03 | $375,987.78 |
DisclosureSEC source: 0000899243-22-039217 · doc4.xml · nonDerivative · entry 3 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 21:42 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 600 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-22-039217 · doc4.xml · derivative · entry 5 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,047 Underlying: Common Stock · 600 shares Expires 2031-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 21:42 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 600 | $28.07 | $16,842.00 |
DisclosureSEC source: 0000899243-22-039217 · doc4.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.03 to $28.09. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.03 to $28.09. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 21:42 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 600 | $23.03 | $13,818.00 |
DisclosureSEC source: 0000899243-22-039217 · doc4.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 00:22 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,297 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-22-039056 · doc4.xml · derivative · entry 6 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,647 Underlying: Common Stock · 1,297 shares Expires 2031-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 00:22 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 1,297 | $28.44 | $36,886.68 |
DisclosureSEC source: 0000899243-22-039056 · doc4.xml · nonDerivative · entry 4 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.72. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.72. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 00:22 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 1,297 | $23.03 | $29,869.91 |
DisclosureSEC source: 0000899243-22-039056 · doc4.xml · nonDerivative · entry 3 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2022 Filed Dec 20, 2022 00:22 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-22-039056 · doc4.xml · derivative · entry 5 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,944 Underlying: Common Stock · 300 shares Expires 2031-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| December 15, 2022 Filed Dec 20, 2022 00:22 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 300 | $28.08 | $8,424.00 |
DisclosureSEC source: 0000899243-22-039056 · doc4.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.